Pmu75 - Is Adopting a Low Price Strategy to Gain Market Access Compatible With a Viable Gene/Cell Therapy Business?

Value in Health - United Kingdom
doi 10.1016/j.jval.2018.09.1911
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

The Domino Procedure Is a Viable Strategy With Acceptable Outcomes

Journal of Cardiac Failure
Cardiovascular MedicineCardiology
2019English

Equitable Access to Gene Therapy: A Call to Action for the American Society of Gene and Cell Therapy

Molecular Therapy
Molecular MedicineMolecular BiologyPharmacologyMedicineGeneticsDrug Discovery
2018English

EGFR Alterations and Response to Anti-Egfr Therapy: Is It a Matter of Gene Amplification or Gene Copy Number Gain?

British Journal of Cancer
Cancer ResearchOncology
2011English

Is Sustainability Reporting a Business Strategy for Firm’s Growth? Empirical Study on the Romanian Capital Market

Sustainability
DevelopmentManagementMonitoringEnvironmental ScienceRenewable EnergyEnergy EngineeringLawSustainabilityPlanningPolicyPower Technologythe EnvironmentGeography
2019English

Reply: EGFR Alterations and Response to Anti-Egfr Therapy: Is It a Matter of Gene Amplification or Gene Copy Number Gain?

British Journal of Cancer
Cancer ResearchOncology
2011English

Pnd110 - Gene Therapy Products – Market Access Situation in Eu and in Slovakia

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Gene Therapy: A Promising Therapeutic Strategy for Malaria

University of Ottawa Journal of Medicine
2018English

Pcp68 - Medical Access Strategy to Improve Access to Innovative and Expensive Therapy in France

Value in Health
MedicineHealth PolicyPublic HealthOccupational HealthEnvironmental
2018English

Making Sustainable Smallholder Tea Farming a Viable Business

2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy